Sana Biotechnology (NASDAQ:SANA) Stock Price Down 4.1%

Sana Biotechnology, Inc. (NASDAQ:SANA)’s stock price was down 4.1% during mid-day trading on Friday . The company traded as low as $4.41 and last traded at $4.43. Approximately 286,001 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 2,300,654 shares. The stock had previously closed at $4.62.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on SANA. HC Wainwright lowered their price target on shares of Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, August 9th. Rodman & Renshaw began coverage on Sana Biotechnology in a report on Wednesday, June 26th. They issued a “buy” rating and a $16.00 price target for the company. Finally, Citigroup raised their price objective on Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Friday, August 9th.

Sana Biotechnology Stock Performance

The company has a market cap of $954.68 million, a price-to-earnings ratio of -2.81 and a beta of 1.45. The stock’s fifty day simple moving average is $5.44 and its two-hundred day simple moving average is $7.12.

Sana Biotechnology (NASDAQ:SANA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). Analysts predict that Sana Biotechnology, Inc. will post -1.13 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Several large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. acquired a new stake in shares of Sana Biotechnology in the fourth quarter valued at about $54,000. Swiss National Bank raised its stake in shares of Sana Biotechnology by 3.5% during the fourth quarter. Swiss National Bank now owns 194,100 shares of the company’s stock valued at $792,000 after purchasing an additional 6,600 shares during the period. Corient Private Wealth LLC lifted its position in shares of Sana Biotechnology by 46.1% during the fourth quarter. Corient Private Wealth LLC now owns 413,360 shares of the company’s stock worth $1,687,000 after purchasing an additional 130,500 shares in the last quarter. Rafferty Asset Management LLC boosted its stake in shares of Sana Biotechnology by 34.7% in the fourth quarter. Rafferty Asset Management LLC now owns 437,614 shares of the company’s stock valued at $1,785,000 after purchasing an additional 112,732 shares during the period. Finally, PFM Health Sciences LP increased its stake in Sana Biotechnology by 51.4% during the 4th quarter. PFM Health Sciences LP now owns 1,883,337 shares of the company’s stock worth $7,684,000 after buying an additional 639,198 shares during the period. 88.23% of the stock is currently owned by institutional investors and hedge funds.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.